1995 Fiscal Year Final Research Report Summary
Adoptive immunotherapy with LAK cells conjugated with epidermal growth factor receptor antibody
| Project/Area Number |
06557111
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | HIROSHIMA UNIVERSITY |
|---|
Principal Investigator |
TAKADA Kazuaki Hiroshima Univ.Sch.Denti.Professor, 歯学部, 教授 (30029970)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKAMOTO Tetsuji Hiroshima Univ.Dental Hospital, Lecturer, 歯学部・附属病院, 講師 (00169153)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Keywords | Oral cancer / LAK cells / Adoptive immunotherapy / epidermal growth factor receptor / Serum-free culture / Interleakin-2 |
|---|
| Research Abstract |
We have developed a serum-free medium designated RDSF for the generation of LAK cells based on RD6F medium, which was originally developed as a serum-free medium for the growth of myeloma and hybridoma cells. The cytotoxic activity of LAK cells generated in RDSF against Raji, K562 and oral cancer cells, is 3-4 times that of LAK cells generated in medium containing 10% human type-AB serum. RDSF medium consisted of nutrient mixture supplemented with transferrin, 2-aminoethanol, 2-mercaptoethanol, sodium selenite and interleukin-2. In this study, we have found that insulin, which has been found to be the most important polypeptide hormone in surum-free media for animal cells, inhibited the generation of cytotoxic activity of LAK cells cultured from pheripheral blood lymphocytes. In addition, we have found that transferrin was an essential component for the growth and generation of LAK cells in serum-free culture. Thses results suggest that RDSF will be usefel for adoptive immunotherapy of cancer and studying factors involved in the growth and differentiatiation of LAK cells.
In addition, we have studied effect of monoclonal antibody (MoAb) to EGF-r designated as 12-93 on the growth of squamous cell carcinoma cells (SCC) and salivary gland adenocarcinoma cells (SAC) in vivo, and targeting immunotherapy using 12-93 MoAb-conjugated LAK cells against oral cancer cells in vitro, A 12-93 MoAb inhibited the growth og SCC and SAC in vivo. The 12-93 conjugated LAK cells showed significantly enhanced cytolysis of 12-93 reactive A431 and HSG cells but not Raji cells which dose not react with 12-93. These results indicated that 12-93 will be aviable altemative to tumor specific MoAb and 12-93-conjugated LAK cells may provide an effective strategy for targeting adoptive immunotherapy of cancer.
|
-
-
-
-
-
-
-
[Publications] Okamoto.T., Tani, R., Sakamoto, A., Yabumoto, M., Osaki, T., Tanaka, Y., Toratani, S., Sato, J.D.and Takada, K.: "Adoptive immunotherapy of oral cancer with lymphokine-activated killer (LAK) cells induced in newly developed serum-free medium." Dentistry in Japan. Vol.32. 67-70 (1995)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Okamoto.T., Tani, Y., Sakamoto, A., Yabumoto, M., Sato, G.H., Sato, J.D.and Takada, K.: "Effects of Insulin and Transferrin on Lymphokine-activated Killer Cells Generation in Serum-Free Medium." J.Immunological Methods. (in press). (1996)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Tani, R., Okamoto, T., Sakamoto, A.: "Yabumoto, M., Toratani, S.and Takada, K.A case of an amelanotic malignant melanoma successfully treated with LAK therapy" Jpn.J.Oral Maxillofac.Surg.Vol.40, No.7. 825-827 (1994)
Description
「研究成果報告書概要(欧文)」より
-
